Abstract
Pompe disease is a metabolic myopathy, due to deficiency of alpha glucosidase, with a wide clinical spectrum. Enzyme replacement therapy is the only available treatment to improve morbidity and mortality, especially in infantile-onset form. However, some patients experience infusion-associated reactions, which may restrict their access to this treatment. We report on two patients (respectively 12 and 3 months old) with infantile-onset Pompe disease and severe cardiomyopathy, that presented with severe reactions during infusion of enzyme replacement therapy and were successfully desensitized with a new individualized protocol. Our protocol, using microdilution and a premedication with antihistamines, corticosteroids, and tranexamic acid, seems safe and effective and it may allow the continuation of therapy in Pompe patients resulting in the reduction of morbidity and mortality related to this disease.
References
Hirschhorn R, AJJ R (2001) Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A et al (eds) The metabolic & molecular bases of inherited disease, vol 8. McGrawHill, New York, pp 3389–3420
Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR et al (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11(3):210–219
Zanichelli A, Azin GM, Wu MA, Suffritti C, Maggioni L, Caccia S et al (2017) Diagnosis, course, and management of angioedema in patients with acquired C1-inhibitor deficiency. J Allergy Clin Immunol Pract 5(5):1307–1313
Gallay L, Petiot P, Durieu I, Streichenberger N, Berard F (2016) SWORD: a simplified desensitization protocol for enzyme replacement therapy in adult Pompe disease. Neuromuscul Disord 26(11):801–804
Cernadas JR, Brockow K, Romano A, Aberer W, Torres MJ, Bircher A et al (2010) General considerations on rapid desensitization for drug hypersensitivity - a consensus statement. Allergy 65(11):1357–1366
Karagol IH, Bakirtas A, Yilmaz O, Topal E, Kucukcongar A, Ezgu FS et al (2014) Desensitisation of the youngest patient with Pompe disease in response to alglucosidase alfa. Allergol Immunopathol (Madr) 42(4):372–375
El-Gharbawy AH, Mackey J, DeArmey S, Westby G, Grinnell SG, Malovrh P et al (2011) An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions. Mol Genet Metab 104(1–2):118–122
Baruteau J, Broomfield A, Crook V, Finnegan N, Harvey K, Burke D et al (2014) Successful desensitisation in a patient with CRIM-positive infantile-onset Pompe disease. JIMD Rep 12:99–102
Lipinski SE, Lipinski MJ, Burnette A, Platts-Mills TA, Wilson WG (2009) Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa. Mol Genet Metab 98(3):319–321
Capanoglu M, Dibek Misirlioglu E, Azkur D, Vezir E, Guvenir H, Gunduz M et al (2016) IgE mediated hypersensitivity and desensitisation with recombinant enzymes in Pompe disease and type I and type VI mucopolysaccharidosis. Int Arch Allergy Immunol 169(3):198–202
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(DOCX 12 kb)
Rights and permissions
About this article
Cite this article
Gragnaniello, V., Fecarotta, S., Pecoraro, A. et al. Desensitization of two young patients with infantile-onset Pompe disease and severe reactions to alglucosidase alfa. Neurol Sci 40, 1453–1455 (2019). https://doi.org/10.1007/s10072-019-03744-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-019-03744-3